AU2019364274C1 - Novel uses - Google Patents
Novel uses Download PDFInfo
- Publication number
- AU2019364274C1 AU2019364274C1 AU2019364274A AU2019364274A AU2019364274C1 AU 2019364274 C1 AU2019364274 C1 AU 2019364274C1 AU 2019364274 A AU2019364274 A AU 2019364274A AU 2019364274 A AU2019364274 A AU 2019364274A AU 2019364274 C1 AU2019364274 C1 AU 2019364274C1
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- pde1 inhibitor
- alkyl
- aryl
- replacement therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748517P | 2018-10-21 | 2018-10-21 | |
| US62/748,517 | 2018-10-21 | ||
| PCT/US2019/057260 WO2020086481A1 (en) | 2018-10-21 | 2019-10-21 | Novel uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2019364274A1 AU2019364274A1 (en) | 2021-06-03 |
| AU2019364274B2 AU2019364274B2 (en) | 2024-10-17 |
| AU2019364274C1 true AU2019364274C1 (en) | 2025-04-10 |
Family
ID=70331921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019364274A Active AU2019364274C1 (en) | 2018-10-21 | 2019-10-21 | Novel uses |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12194042B2 (enExample) |
| EP (1) | EP3866808A4 (enExample) |
| JP (1) | JP7480135B2 (enExample) |
| KR (1) | KR20210080418A (enExample) |
| CN (1) | CN113194955A (enExample) |
| AU (1) | AU2019364274C1 (enExample) |
| BR (1) | BR112021007571A2 (enExample) |
| CA (1) | CA3117148A1 (enExample) |
| IL (1) | IL282396A (enExample) |
| MX (1) | MX2021004531A (enExample) |
| WO (1) | WO2020086481A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220184240A1 (en) * | 2019-04-12 | 2022-06-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US12410175B2 (en) | 2019-09-03 | 2025-09-09 | Intra-Cellular Therapies, Inc. | Compounds |
| EP4284806A4 (en) * | 2021-01-27 | 2025-02-26 | Intra-Cellular Therapies, Inc. | Salt crystals |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1585771A (zh) * | 2001-11-09 | 2005-02-23 | 先灵公司 | 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂 |
| PT2152712E (pt) | 2007-05-11 | 2012-02-29 | Pfizer | Compostos amino-heterocíclicos |
| EP2939676A1 (en) * | 2007-12-06 | 2015-11-04 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
| TW201206937A (en) * | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| CA2961212C (en) | 2014-09-17 | 2024-02-06 | Intra-Cellular Therapies, Inc. | Compounds and methods |
| EP4112053B1 (en) | 2016-10-11 | 2024-02-14 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) | Treatment of synucleinopathies |
-
2019
- 2019-10-21 WO PCT/US2019/057260 patent/WO2020086481A1/en not_active Ceased
- 2019-10-21 US US17/287,478 patent/US12194042B2/en active Active
- 2019-10-21 CN CN201980084405.9A patent/CN113194955A/zh active Pending
- 2019-10-21 MX MX2021004531A patent/MX2021004531A/es unknown
- 2019-10-21 EP EP19877180.0A patent/EP3866808A4/en active Pending
- 2019-10-21 KR KR1020217013853A patent/KR20210080418A/ko not_active Ceased
- 2019-10-21 JP JP2021521516A patent/JP7480135B2/ja active Active
- 2019-10-21 AU AU2019364274A patent/AU2019364274C1/en active Active
- 2019-10-21 BR BR112021007571-2A patent/BR112021007571A2/pt unknown
- 2019-10-21 CA CA3117148A patent/CA3117148A1/en active Pending
-
2021
- 2021-04-18 IL IL282396A patent/IL282396A/en unknown
-
2024
- 2024-12-03 US US18/967,095 patent/US20250090536A1/en active Pending
Non-Patent Citations (5)
| Title |
|---|
| ALEXANDRE E. MEDINA: "Therapeutic Utility of Phosphodiesterase Type I Inhibitors in Neurological Conditions", FRONTIERS IN NEUROSCIENCE, vol. 5, 18 February 2011 (2011-02-18), pages 1 - 5, XP055289486, DOI: 10.3389/fnins.2011.00021 * |
| DAVIS ROBERT ET AL: ANNALS OF NEUROLOGY, vol. 84, no. Suppl 22, 5 October 2018 (2018-10-05), pages S191 - S192, * |
| GIORGI M. ET AL: EUROPEAN JOURNAL OF NEUROSCIENCE., vol. 28, no. 5, 1 September 2008 (2008-09-01), GB, pages 941 - 950, XP055966379, ISSN: 0953-816X, DOI: 10.1111/j.1460-9568.2008.06387.x * |
| INTRA-CELLULAR THERAPIES ET AL: "Intra-Cellular Therapies Presents Data on ITI-214 at the 2018 American Academy of Neurology Annual Meeting | Intra-Cellular Therapies Inc.", 26 April 2018 * |
| NICCOLINI FLAVIA ET AL: CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, HEIDELBERG, DE, vol. 72, no. 11, 15 February 2015 (2015-02-15), pages 2107 - 2117, XP035501546, ISSN: 1420-682X, * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113194955A (zh) | 2021-07-30 |
| JP2022505471A (ja) | 2022-01-14 |
| AU2019364274B2 (en) | 2024-10-17 |
| US20250090536A1 (en) | 2025-03-20 |
| BR112021007571A2 (pt) | 2021-07-27 |
| US20210379072A1 (en) | 2021-12-09 |
| WO2020086481A1 (en) | 2020-04-30 |
| MX2021004531A (es) | 2021-09-10 |
| US12194042B2 (en) | 2025-01-14 |
| KR20210080418A (ko) | 2021-06-30 |
| IL282396A (en) | 2021-06-30 |
| EP3866808A4 (en) | 2023-04-12 |
| JP7480135B2 (ja) | 2024-05-09 |
| EP3866808A1 (en) | 2021-08-25 |
| AU2019364274A1 (en) | 2021-06-03 |
| CA3117148A1 (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250090536A1 (en) | Uses | |
| US9198924B2 (en) | Organic compounds | |
| JP6696904B2 (ja) | 製剤および医薬組成物 | |
| US8664207B2 (en) | Organic compounds | |
| EP3509589B1 (en) | Novel uses | |
| US11285153B2 (en) | Substituted pyrimidine piperazine compound and use thereof | |
| JP7749896B2 (ja) | 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター | |
| US20260053808A1 (en) | Novel uses | |
| US20210338679A1 (en) | Novel uses | |
| EP3725789A1 (en) | 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns) | |
| RU2836384C2 (ru) | Новые применения | |
| HK40057178A (en) | Novel uses | |
| US11628171B2 (en) | Method for treating brain or nerve injury | |
| US20230355625A1 (en) | Methods of treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 DEC 2024 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 20 DEC 2024 |
|
| FGA | Letters patent sealed or granted (standard patent) |